The company will postpone the annual shareholders’ meeting to June 21, 2021 in accordance with the instructions of FSC (distribution of electronic voting shareholders’ complimentary gift)
2021.May.20
The Company will postpone the Annual Shareholders' meeting on June 21, 2021 in accordance with the instructions of FSC
2021.May.19
Supplementary statement for 2021 shareholders’ meeting (change of location)
2021.May.13
OBI-999 completes its Phase 1 safety evaluation and demonstrates its safety with no major concerns, proceeding to Phase 2 as planned
2021.May.07
Supplementary statement for 2021 shareholders’ meeting (additional matters)
2021.May.07
Announcement that the consolidated financial statements for the first quarter of 2021 were authorized for issuance by the Board of Directors
2021.May.07
Updates on the planned allocation of the cash raised from the 2018 fundraising
2021.May.06
The active cancer immunotherapy OBI-822, Adagloxad Simolenin, has been granted by South African Health Products Regulatory Authority (SAHPRA) to proceed to Phase III human clinical study
2021.May.05
OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned
2021.Apr.29
Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company's Board of Directors resolved to convene the 2021 Annual General Shareholders' Meeting
